Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Julphar
Johnson and Johnson
US Army
Cerilliant
AstraZeneca
Cipla
Moodys
Colorcon
Federal Trade Commission

Generated: August 18, 2017

DrugPatentWatch Database Preview

PLENAXIS Drug Profile

« Back to Dashboard

What is the patent landscape for Plenaxis, and when can generic versions of Plenaxis launch?

Plenaxis is a drug marketed by Speciality European and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-nine patent family members in thirty-four countries.

The generic ingredient in PLENAXIS is abarelix. Additional details are available on the abarelix profile page.

Summary for Tradename: PLENAXIS

Patents:3
Applicants:1
NDAs:1
Bulk Api Vendors: see list15
Clinical Trials: see list3
Patent Applications: see list3,515
Drug Prices:see details
DailyMed Link:PLENAXIS at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PLENAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: PLENAXIS

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe
PLENAXIS
► Subscribe

International Patent Family for Tradename: PLENAXIS

Country Document Number Estimated Expiration
Brazil9714015► Subscribe
Turkey9901382► Subscribe
Germany69738460► Subscribe
Australia735174► Subscribe
Poland199121► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PLENAXIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0015France► SubscribePRODUCT NAME: ABARELIX, EVENTUELLEMENT SOUS FORME DE SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE IN FRANCE: 69026150 DU 20101126; REGISTRATION NO/DATE AT EEC: 57890.00.00 DU 20050922
C/GB11/006United Kingdom► SubscribePRODUCT NAME: ABARELIX, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE - 20050922; UK PL32828/001 20100917
2011 00004Denmark► SubscribePRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922
00484Netherlands► SubscribePRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922
90014-9Sweden► SubscribePRODUCT NAME: ABARELIX
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Fuji
Teva
Cantor Fitzgerald
Johnson and Johnson
McKesson
Harvard Business School
Covington
QuintilesIMS
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot